Pharma Should Be Excluded From Guideline Development – NEJM Editorial
Executive Summary
Standards for the development and adoption of treatment guidelines should be established in light of efforts by industry to manipulate guidelines for commercial purposes, NIH Critical Care Medicine Department senior investigators assert